Tevard Biosciences was founded by Daniel Fischer and Warren Lammert, parents of girls with Dravet Syndrome and Harvey Lodish, a professor at MIT and Whitehead Institute for Biomedical Research.
Tevard Biosciences is developing gene therapy platforms to target rare diseases such as Dravet syndrome and disorders caused by haploinsufficiency and/or premature stop codons, which traditional gene therapy approaches do not target. Dravet syndrome is also known as Severe Myoclonic Epilepsy of Infancy (SMEI), a condition caused by a mutation in the SCN1A gene required for brain cell function, in 85% of cases.
The company is housed at LabCentral, a shared laboratory space for launching life-sciences and biotech startups. Tevard Biosciences won a Pfizer-sponsored LabCentral “Golden Ticket” in 2018, which provides one year of bench space for one scientist with infrastructure and services.
Tevard Biosciences was founded by Daniel Fischer and Warren Lammert.
Member Board Of Directors
Documentaries, videos and podcasts
- Gene therapyGene Therapy uses genes to treat or prevent disease. Types of gene therapy include replacing a mutated gene with a healthy copy, inactivating or knocking out a mutated gene or introducing a new gene to fight disease.
- Harvey LodishAmerican biologist
- Dravet syndromeAn epilepsy that is characterized by frequent febrile seizures with onset before 1 year.